Drug Information
| Drug General Information | |||||
|---|---|---|---|---|---|
| Drug ID |
D00GNI
|
||||
| Former ID |
DIB008516
|
||||
| Drug Name |
REGN-727
|
||||
| Synonyms |
Alirocumab; Alirocumab); RENG-727; SAR-236553; Anti-PCSK9 antibody (hypercholesterolemia), Regeneron/sanofi-aventis
|
||||
| Drug Type |
Antibody
|
||||
| Company |
Sanofi; Novo Nordisk
|
||||
| Target and Pathway | |||||
| Target(s) | Proprotein convertase subtilisin/kexin type 9 | Target Info | [531924], [532996], [533123] | ||
| WikiPathways | PCSK9-mediated LDLR degradation | ||||
| References | |||||
| Ref 533123 | 2014 FDA drug approvals. Nat Rev Drug Discov. 2015 Feb;14(2):77-81. | ||||
| Ref 541842 | (http://www.guidetopharmacology.org/) Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Ligand id: 6744). | ||||
| Ref 531924 | Effect of a monoclonal antibody to PCSK9, REGN727/SAR236553, to reduce low-density lipoprotein cholesterol in patients with heterozygous familial hypercholesterolaemia on stable statin dose with or without ezetimibe therapy: a phase 2 randomised controlled trial. Lancet. 2012 Jul 7;380(9836):29-36. | ||||
| Ref 532996 | The dyslipidaemia market. Nat Rev Drug Discov. 2014 Nov;13(11):807-8. | ||||
| Ref 533123 | 2014 FDA drug approvals. Nat Rev Drug Discov. 2015 Feb;14(2):77-81. | ||||
If You Find Any Error in Data or Bug in Web Service, Please Kindly Report It to Dr. Zhou and Dr. Zhang.